2.07
전일 마감가:
$2.02
열려 있는:
$2
하루 거래량:
1.57M
Relative Volume:
0.59
시가총액:
$96.42M
수익:
-
순이익/손실:
$-37.65M
주가수익비율:
-1.2395
EPS:
-1.67
순현금흐름:
$-24.14M
1주 성능:
+12.50%
1개월 성능:
+5.08%
6개월 성능:
+129.97%
1년 성능:
-47.73%
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
명칭
Reviva Pharmaceuticals Holdings Inc
전화
(408) 501-8881
주소
10080 N WOLFE ROAD, CUPERTINO
RVPH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RVPH
Reviva Pharmaceuticals Holdings Inc
|
2.07 | 96.42M | 0 | -37.65M | -24.14M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-09-20 | 개시 | ROTH MKM | Buy |
2023-06-08 | 개시 | The Benchmark Company | Speculative Buy |
2022-01-24 | 개시 | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Buy" by Analysts - MarketBeat
Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World
How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News
Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Reviva CEO to Showcase CNS Pipeline at Major Healthcare Conference - StockTitan
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decline in Short Interest - MarketBeat
Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire
Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com
Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan
HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World
HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World
Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Unusual Options Activity - Benzinga
Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH) - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Given Buy Rating at D. Boral Capital - MarketBeat
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 35.9% in December - MarketBeat
Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.25 - Defense World
Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals stock rated buy by Roth/MKM, backed by Phase 3 results - Investing.com Nigeria
Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Buy at Maxim Group - Defense World
Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to “Strong-Buy” at Roth Capital - Defense World
Maxim Group raises Reviva stock to Buy, sets new target By Investing.com - Investing.com Australia
Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $11.25 - MarketBeat
Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded at Roth Capital - MarketBeat
Maxim Group Upgrades Reviva Pharmaceuticals (NASDAQ:RVPH) to Buy - MarketBeat
Roth MKM Initiates Coverage of Reviva Pharmaceuticals Holdings (RVPH) with Buy Recommendation - MSN
Maxim Group raises Reviva stock to Buy, sets new target - Investing.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Coverage Initiated at Roth Mkm - MarketBeat
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit -January 07, 2025 at 08:02 am EST - Marketscreener.com
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit - GlobeNewswire
Reviva Pharmaceuticals CEO to Present at Lytham Partners Healthcare Summit 2025 - StockTitan
Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals to Participate in the UBS Global Healthcare Conference - Marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for RVPH Issued By Zacks Small Cap - MarketBeat
RVPH: Preliminary OLE Readout - Yahoo Finance
Reviva Pharmaceuticals Strengthens Financial Position with Offering - Yahoo Finance
Reviva Pharmaceuticals Announces Positive Preliminary Data from RECOVER Trial – - Defense World
Reviva Pharmaceuticals Holdings Inc (RVPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):